Cancer Research UK appoints new director to lead its Centre for Drug Development

12 December 2023

Cancer Research UK has appointed industry veteran Dr Lars Erwig as the new director for its Centre for Drug Development, the world's only charity-funded drug development facility.

With Cancer Research UK’s aim to beat cancer, the center has a critical role to play in partnering with others to ensure that pre-clinical and early-phase clinical projects with the highest potential for patient benefit are prioritised and rapidly advanced.

In his new role, Dr Erwig will be responsible for shaping an exciting and cutting-edge portfolio of first-in-human trials for the charity, working closely with Cancer Research UK’s academic research community and partners across industry and biotech. He brings a wealth of experience and expertise in academia as well as in the pharmaceutical and biotechnology sectors, having joined from Johnson & Johnson (NYSE: JNJ), where he was vice president for external innovation, responsible for growing academic and industry networks and advancing external opportunities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK